Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw unusually large options trading activity on Wednesday. Traders acquired 5,966 call options on the company. This is an increase of 1,576% compared to the typical daily volume of 356 call options.
In related news, SVP Daphne Quimi sold 7,000 shares of the stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $99,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John F. Crowley sold 449,295 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the completion of the sale, the chief executive officer now directly owns 380,723 shares in the company, valued at $5,455,760.59. The disclosure for this sale can be found here. Insiders sold a total of 826,114 shares of company stock worth $11,791,184 over the last three months. 3.40% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of the company. Sage Capital Advisors llc purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $154,000. GSA Capital Partners LLP purchased a new position in Amicus Therapeutics during the third quarter valued at approximately $309,000. Iguana Healthcare Management LLC purchased a new position in Amicus Therapeutics during the third quarter valued at approximately $905,000. Sterling Capital Management LLC purchased a new position in Amicus Therapeutics during the third quarter valued at approximately $218,000. Finally, Neuberger Berman Group LLC purchased a new position in Amicus Therapeutics during the third quarter valued at approximately $196,000.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The company had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business’s revenue was up 419.0% compared to the same quarter last year. During the same period last year, the business posted ($0.33) earnings per share. research analysts anticipate that Amicus Therapeutics will post -1.56 EPS for the current year.
A number of analysts recently weighed in on the stock. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 19th. Goldman Sachs Group reaffirmed a “neutral” rating and set a $17.00 target price on shares of Amicus Therapeutics in a research report on Friday, October 6th. Chardan Capital reaffirmed a “buy” rating and set a $18.50 target price (up from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $17.81.
COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics Sees Unusually Large Options Volume (FOLD)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/06/amicus-therapeutics-sees-unusually-large-options-volume-fold.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.